tegobuvir (GS 9190) / Gilead  >>  Phase 2
Welcome,         Profile    Billing    Logout  

8 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
tegobuvir (GS 9190) / Gilead
NCT00743795 / 2008-004527-31: Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection

Completed
2b
252
US, Europe
placebo, GS-9190, Peginterferon Alfa 2a, PEG, Ribavirin, RBV
Gilead Sciences
HCV Infection
07/09
09/13
NCT01271790 / 2010-023952-10: A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

Completed
2b
245
US, Europe
Tegobuvir (GS-9190), GS-9451, Pegasys®, Copegus®, Tegobuvir placebo, GS-9451 placebo
Gilead Sciences
Hepatitis C, Chronic
01/13
09/13
NCT01225380 / 2010-020911-35: A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

Checkmark EASL 2012
Apr 2012 - Apr 2012: EASL 2012
Completed
2b
324
US, Canada, Europe
GS-9190, GS-9256, Pegasys®, Copegus®, GS-9190 placebo, GS-9256 placebo
Gilead Sciences
Chronic Hepatitis C Infection
01/13
09/13
NCT01371578: Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection

Completed
2b
163
US
GS-5885 tablet, GS-9451 tablet, peginterferon alfa-2a, ribavirin tablet
Gilead Sciences
Hepatitis C, Chronic
03/13
03/13
NCT01072695 / 2009-013690-18: Efficacy and Safety Study of GS-9256 and GS-9190 Alone and in Combination With Ribavirin for 28 Days in Patients With Chronic Hepatitis C Virus Infection

Checkmark EASL 2012
Mar 2011 - Mar 2011: EASL 2012
Completed
2
46
Europe
GS-9256, GS-9190, Ribavirin, COPEGUS, Peginterferon alfa-2a, Pegasys
Gilead Sciences
HCV Infection
10/10
01/12
NCT01353248 / 2011-000944-43: GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection

Checkmark
Feb 2014 - Feb 2014: 
Checkmark EASL 2013
Apr 2013 - Apr 2013: EASL 2013
Checkmark EASL 2013
More
Completed
2
141
US
GS-5885, Tegobuvir, GS-9451, ribavirin tablet
Gilead Sciences
Hepatitis C, Chronic
10/12
03/13
NCT01434498: GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection

Checkmark EASL 2012
Apr 2012 - Apr 2012: EASL 2012
Completed
2
163
US, Canada
GS-5885 tablet, GS-9451 tablet, tegobuvir capsule, ribavirin tablet, placebo matching ribavirin tablet, placebo matching tegobuvir capsule
Gilead Sciences
Chronic Genotype 1a or 1b HCV Infection
01/13
01/13
NCT01435226 / 2011-002748-28: GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection

Completed
2
170
US, Europe
GS-5885, GS-9451, tegobuvir, placebo to match tegobuvir, placebo to match RBV, Ribavirin
Gilead Sciences
Hepatitis C, Chronic
01/13
07/13

Download Options